Market Overview:
The global metabotropic glutamate receptor 7 market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of neurological disorders, rising geriatric population, and growing demand for novel therapeutics. By type, the market is segmented into JBPOS-0101, PGT-117, ADX-71743, and others. The JBPOS-0101 segment is expected to account for the largest share of the global metabotropic glutamate receptor 7 market in 2018. By application, the market is divided into generalized anxiety disorder (GAD), infantile spasm (IS), status epilepticus (SE), and others. The GAD segment accounted for majority of the share in 2017 and is projected to maintain its dominance during the forecast period.
Product Definition:
Metabotropic glutamate receptor 7 (mGluR7) is a protein that in humans is encoded by the GRM7 gene. mGluR7 is a metabotropic glutamate receptor. Glutamate is the most common excitatory neurotransmitter in the brain, and mGluRs are proteins that bind glutamate and play an important role in synaptic plasticity and neurodevelopment.
JBPOS-0101:
JBPOS-0101 is a drug that is under clinical investigation for the treatment of schizophrenia. JBPOS-0101 has completed phase 1 study and currently in the process of finishing phase 2 & 3 studies. The drug has also received Orphan Drug Designation from FDA for its use in treating schizophrenia.
PGT-117:
PGT-117 is a drug that is under clinical investigation for the treatment of Dravet Syndrome, a rare chronic disorder associated with epilepsy. PGT-117 has also shown efficacy as a single agent in treating severe myoclonus in patients with muscular dystrophy and multiple sclerosis.
Application Insights:
Generalized anxiety disorder was the most prominent application of MBR7 in 2017. The drug has been approved by the U.S. FDA for treatment of Generalized Anxiety Disorder (GAD) and is under clinical trials for other anxiety disorders such as social anxiety disorder, panic disorder, and phobias. In addition, it is also being studied for use in premenstrual syndrome (PMS).
The infantile spasm segment held a significant share of the global market revenue in 2017 owing to increasing incidence rates of this condition across the globe especially during infancy period itself which usually persists throughout life span causing severe developmental delays.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its position during the forecast period. This can be attributed to increasing awareness about mental health, availability of effective treatment, and high demand for novel therapeutics. Moreover, presence of key players in this region will help maintain dominance throughout the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the coming years owing to rising prevalence of anxiety disorders coupled with growing awareness about available treatment options in emerging economies such as China and India. Furthermore, increasing disposable income levels are also likely to contribute toward regional growth over the next eight years due to rapid development that has taken place since 2015 when this study was first published in Metabotropic Glutamate Receptors (2018).
The European market for metabotropic glutamate receptors consists mainly of Germany and U.K., which accounted for a significant share within Europe’s overall revenue generation in 2017 owing Kuntz et al.
Growth Factors:
- Increasing prevalence of neurological disorders such as Alzheimer's disease, epilepsy, and Huntington's disease is expected to drive the growth of the metabotropic glutamate receptor 7 market.
- Growing demand for novel therapeutics for the treatment of various neurological disorders is anticipated to boost the growth of this market in the near future.
- Rising research and development expenditure by pharmaceutical companies for new drug discovery is projected to propel the metabotropic glutamate receptor 7 market in coming years.
- increasing geriatric population base is likely to create lucrative opportunities for players operating in this market over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Metabotropic Glutamate Receptor 7 Market Research Report
By Type
JBPOS-0101, PGT-117, ADX-71743, Others
By Application
Generalized Anxiety Disorder, Infantile Spasm, Status Epilepticus, Others
By Companies
Addex Therapeutics Ltd, Aevi Genomic Medicine Inc, Bio-Pharm Solutions Co Ltd, Pragma Therapeutics SAS, Addex Therapeutics Ltd
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
171
Number of Tables & Figures
120
Customization Available
Yes, the report can be customized as per your need.
Global Metabotropic Glutamate Receptor 7 Market Report Segments:
The global Metabotropic Glutamate Receptor 7 market is segmented on the basis of:
Types
JBPOS-0101, PGT-117, ADX-71743, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Generalized Anxiety Disorder, Infantile Spasm, Status Epilepticus, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Addex Therapeutics Ltd
- Aevi Genomic Medicine Inc
- Bio-Pharm Solutions Co Ltd
- Pragma Therapeutics SAS
- Addex Therapeutics Ltd
Highlights of The Metabotropic Glutamate Receptor 7 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- JBPOS-0101
- PGT-117
- ADX-71743
- Others
- By Application:
- Generalized Anxiety Disorder
- Infantile Spasm
- Status Epilepticus
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Metabotropic Glutamate Receptor 7 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Metabotropic glutamate receptor 7 (mGluR7) is a type of glutamate receptor that is found in the central nervous system. mGluR7 plays a role in controlling neuronal activity and has been shown to be involved in various neurological disorders, such as epilepsy and autism.
Some of the key players operating in the metabotropic glutamate receptor 7 market are Addex Therapeutics Ltd, Aevi Genomic Medicine Inc, Bio-Pharm Solutions Co Ltd, Pragma Therapeutics SAS, Addex Therapeutics Ltd.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Metabotropic Glutamate Receptor 7 Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Metabotropic Glutamate Receptor 7 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Metabotropic Glutamate Receptor 7 Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Metabotropic Glutamate Receptor 7 Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Metabotropic Glutamate Receptor 7 Market Size & Forecast, 2020-2028
4.5.1 Metabotropic Glutamate Receptor 7 Market Size and Y-o-Y Growth
4.5.2 Metabotropic Glutamate Receptor 7 Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 JBPOS-0101
5.2.2 PGT-117
5.2.3 ADX-71743
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Generalized Anxiety Disorder
6.2.2 Infantile Spasm
6.2.3 Status Epilepticus
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Metabotropic Glutamate Receptor 7 Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Metabotropic Glutamate Receptor 7 Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 JBPOS-0101
9.6.2 PGT-117
9.6.3 ADX-71743
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Generalized Anxiety Disorder
9.10.2 Infantile Spasm
9.10.3 Status Epilepticus
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 JBPOS-0101
10.6.2 PGT-117
10.6.3 ADX-71743
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Generalized Anxiety Disorder
10.10.2 Infantile Spasm
10.10.3 Status Epilepticus
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 JBPOS-0101
11.6.2 PGT-117
11.6.3 ADX-71743
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Generalized Anxiety Disorder
11.10.2 Infantile Spasm
11.10.3 Status Epilepticus
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 JBPOS-0101
12.6.2 PGT-117
12.6.3 ADX-71743
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Generalized Anxiety Disorder
12.10.2 Infantile Spasm
12.10.3 Status Epilepticus
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 JBPOS-0101
13.6.2 PGT-117
13.6.3 ADX-71743
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Generalized Anxiety Disorder
13.10.2 Infantile Spasm
13.10.3 Status Epilepticus
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Metabotropic Glutamate Receptor 7 Market: Competitive Dashboard
14.2 Global Metabotropic Glutamate Receptor 7 Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Addex Therapeutics Ltd
14.3.2 Aevi Genomic Medicine Inc
14.3.3 Bio-Pharm Solutions Co Ltd
14.3.4 Pragma Therapeutics SAS
14.3.5 Addex Therapeutics Ltd
